ACOR - Acorda Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
211,063
471,433
588,287
519,601
Cost of Revenue
49,329
99,310
135,714
108,109
Gross Profit
161,734
372,123
452,573
411,492
Operating Expenses
Research Development
78,118
106,383
166,105
203,437
Selling General and Administrative
188,441
172,254
181,619
235,437
Total Operating Expenses
282,834
278,637
347,724
438,874
Operating Income or Loss
-121,100
93,486
104,849
-27,382
Interest Expense
21,573
21,597
18,664
16,527
Total Other Income/Expenses Net
-254,336
-54,984
-338,206
1,302
Income Before Tax
-392,576
20,423
-251,885
-42,268
Income Tax Expense
-63,545
-13,259
-28,526
-6,665
Income from Continuing Operations
-329,031
33,682
-223,359
-35,603
Net Income
-329,031
33,682
-223,359
-34,618
Net Income available to common shareholders
-329,031
33,682
-223,359
-34,618
Reported EPS
Basic
-
0.72
-4.86
-0.76
Diluted
-
0.71
-4.86
-0.76
Weighted average shares outstanding
Basic
-
47,010
45,999
45,259
Diluted
-
47,341
45,999
45,259
EBITDA
-
53,499
-209,987
-4,159